Glaucoma remains a primary cause of irreversible visual impairment worldwide, requiring sustained intraocular pressure reduction to prevent blindness. When conventional filtration fails, ophthalmologists frequently perform glaucoma tube shunt surgery to prevent progressive optic neuropathy. However, excessive postoperative conjunctival scarring around the drainage plate can compromise long-term surgical success. Consequently, clinicians continue to debate whether adjunctive anti-scarring agents like mitomycin-C provide meaningful clinical benefit during shunt implantation. Fortunately, a recent comprehensive meta-analysis provides critical evidence regarding their efficacy and safety.

Biological Mechanisms of Anti-Scarring Agents

Surgical trauma during shunt implantation unavoidably initiates a robust wound-healing cascade involving tissue inflammation and fibroblast migration. In conventional filtration surgery, this fibrotic reaction seals the drainage bleb and raises intraocular pressure. Similarly, during tube shunt procedures, surgical trauma triggers local Tenon fibroblasts to deposit dense collagen around the equatorial reservoir plate. Consequently, this progressive encapsulation creates an outflow barrier that hinders aqueous absorption.

To modulate this fibrotic process, surgeons historically borrowed antimetabolites from trabeculectomy protocols. For example, mitomycin-C permanently blocks fibroblast proliferation by crosslinking cellular DNA strands. In addition, 5-fluorouracil halts pyrimidine synthesis, while corticosteroids suppress leukocyte infiltration and capillary permeability. Furthermore, vascular endothelial growth factor inhibitors limit tissue edema and neovascularization. Therefore, ophthalmologists anticipated that intraoperative antifibrotic administration would attenuate capsule thickness and lower long-term filtration resistance. Nevertheless, tube implants possess distinct hydrodynamic properties compared to trabeculectomy blebs.

Systematic Review and Meta-Analysis Methodology

To resolve persistent clinical debates, researchers conducted a comprehensive systematic review registered prospectively in the PROSPERO international database. Specifically, investigators queried major electronic databases, including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. They searched for clinical trials and cohort studies comparing adjunctive anti-scarring agents against surgery alone. Furthermore, the selection criteria encompassed diverse glaucoma etiologies managed with valve or non-valve drainage implants.

Ultimately, the rigorous screening process identified twenty-eight eligible studies comprising 1,621 eyes. Among these, twelve were randomized controlled trials involving 624 eyes, while sixteen were comparative cohort studies containing 997 eyes. Eleven studies specifically evaluated intraoperative mitomycin-C, seven examined corticosteroids, six tested anti-VEGF agents, and two analyzed 5-fluorouracil. Additionally, two studies investigated combined antifibrotic regimens. The authors systematically extracted primary outcomes, including intraocular pressure changes, medication requirements, and postoperative complications at three, six, and twelve months. Consequently, this expansive meta-analysis established an exceptionally robust comparative dataset.

Pressure Reduction in Glaucoma Tube Shunt Surgery

Intraocular pressure lowering represents the cornerstone of glaucoma management and visual preservation. Surprisingly, the pooled meta-analysis demonstrated that adjunctive anti-scarring agents do not produce statistically significant intraocular pressure reductions compared to control procedures. Specifically, the pooled mean differences measured 1.99 mmHg at month three, 1.06 mmHg at month six, and 1.15 mmHg at month twelve. None of these differences achieved statistical significance at any observed follow-up interval.

Moreover, isolated subgroup analyses evaluating mitomycin-C or anti-VEGF medications confirmed this lack of therapeutic divergence. While laboratory studies suggest thinner capsules with antimetabolites, fluid transudation depends primarily on overall plate surface area rather than capsule thickness alone. Because large plate reservoirs provide extensive filtration areas, aqueous humor diffuses steadily despite moderate fibrous remodeling. Furthermore, intrinsic internal lumen resistance and valve opening pressure dictate early postoperative outflow dynamics. Consequently, pharmacologic suppression of peri-endplate fibroblasts fails to deliver meaningful additional pressure reduction. Hence, clinicians cannot rely on antimetabolites to enhance absolute surgical pressure control.

Impact on Postoperative Glaucoma Medication Burden

Although absolute pressure levels remained comparable, adjunctive antifibrotic therapy exerted a striking effect on postoperative medication dependence. Indeed, patients receiving anti-scarring agents required significantly fewer topical hypotensive drops throughout the twelve-month observation period. Specifically, pooled analyses documented statistically significant drop reductions at months three, six, and twelve, averaging roughly half a medication fewer per day.

Furthermore, detailed subgroup analysis revealed that mitomycin-C primarily drove this consistent medication-sparing benefit. By modestly attenuating peri-endplate collagen density, mitomycin-C preserved bleb permeability and prevented early hypertensive spikes. Consequently, treating clinicians maintained target pressure thresholds using fewer supplemental topical agents. This reduction in daily eyedrop burden delivers immense practical value to patients. Decreased topical therapy reduces ocular surface irritation, minimizes preservative-induced toxicity, and enhances daily therapeutic adherence. In addition, fewer prescriptions ease cumulative pharmacy expenditures for elderly individuals. Therefore, while adjunctive antimetabolites do not lower baseline pressure numbers, they effectively reduce polypharmacy and protect the delicate ocular surface.

Safety Profiles, Complications, and Clinical Recommendations

When incorporating antimetabolites into incisional surgery, ophthalmic surgeons must rigorously assess complication risks. Fortunately, the meta-analysis found no significant increase in sight-threatening adverse events among eyes receiving anti-scarring adjuncts. Specifically, rates of early hypotony, anterior chamber flattening, and choroidal detachment remained comparable between treated and untreated groups. Furthermore, the investigators observed no statistically significant rise in tube erosion or late endophthalmitis.

Nevertheless, surgeons must remain vigilant regarding cytotoxic tissue injury. Because mitomycin-C impairs conjunctival vascularity, improper sponge application can predispose friable tissue to late conjunctival thinning and exposure. Therefore, surgeons should meticulously avoid placing soaked sponges near incision borders or patch graft edges. Moreover, unselected routine antimetabolite administration remains unwarranted given the lack of superior pressure reduction. Instead, specialists should reserve adjunctive mitomycin-C for specific patients who face high cicatrization risks or desperately need medication reduction. Ultimately, thorough surgical technique and prudent patient selection ensure favorable outcomes without introducing unnecessary operative hazards.

Frequently Asked Questions

Do anti-scarring agents lower intraocular pressure in tube shunt surgery?

Current systematic reviews and meta-analyses show that adjunctive anti-scarring agents, including mitomycin-C, do not achieve statistically significant additional intraocular pressure reduction compared to tube shunt surgery alone. Because glaucoma drainage implants rely primarily on large endplate surface area and tube mechanics rather than thin filtering blebs, pharmaceutical inhibition of fibrosis produces minimal changes in baseline outflow resistance throughout the first postoperative year.

Why do patients treated with mitomycin-C require fewer postoperative eyedrops?

Although overall intraocular pressure remains comparable between groups, adjunctive mitomycin-C suppresses excessive collagen deposition and myofibroblast migration around the implant endplate. Consequently, this modulation of peri-endplate wound healing helps maintain capsule permeability and blunts early postoperative hypertensive phases. As a direct result, clinicians can achieve targeted intraocular pressure goals while prescribing significantly fewer topical pressure-lowering medications, thereby reducing ocular surface toxicity and improving patient compliance over time.

What are the primary safety concerns when using antifibrotic adjuncts?

Antifibrotic medications carry potential cytotoxic risks that require careful intraoperative handling. In glaucoma tube shunt procedures, high concentrations or misplaced sponges can induce avascular scleral necrosis, conjunctival breakdown, and subsequent implant extrusion. Furthermore, impaired tissue healing increases the risk of delayed bleb leaks, persistent hypotony, and devastating endophthalmitis. Therefore, surgeons must ensure precise localization beneath the Tenon capsule and irrigate tissues thoroughly to prevent catastrophic tissue destruction.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice or relied upon for clinical practice. Procedures, medications, and treatments discussed herein may not be standard, fully validated, or widely accessible. Always use independent clinical judgment, follow current professional standards, and evaluate potential risks before considering novel approaches. Consult qualified healthcare professionals for diagnosis and treatment options. Refer to the latest local and national guidelines for clinical practice.

References

1. Tan VZZ et al. Do Adjunctive Anti-scarring Agents Including Mitomycin-C Improve Glaucoma Tube Shunt Surgery: Systematic Review and Meta-analysis. Ophthalmic Epidemiol. 2026 Nov 11. doi: 10.1080/09286586.2026.2713590. PMID: 43012868.


2. Figueiredo R, et al. The efficacy of adjunctive mitomycin C and/or anti-VEGF agents on glaucoma tube shunt drainage device surgeries: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2024;262(10):3121-3134.


3. Gedde SJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803.